Strategy of antibody-drug conjugates in preclinical safety evaluation
10.3867/j.issn.1000-3002.2016.01.002
- VernacularTitle:抗体药物偶联物临床前安全性评价策略
- Author:
Min HONG
;
Xiaoping ZHAO
;
Jing MA
- Publication Type:Journal Article
- Keywords:
antibody-drug conjugates;
safety evaluation;
tumors;
molecular targeted therapy
- From:
Chinese Journal of Pharmacology and Toxicology
2016;(1):7-12
- CountryChina
- Language:Chinese
-
Abstract:
Recently,increasing cancer researches focus on antibody-drug conjugates(ADCs) which can improve the anti-tumor potency with less adverse effect while benefiting patients in the future. However,safety evaluation of ADCs is a big challenge because of complex components as well as in experience in preclinical studies. In this review,the authors reviewed the mode of action,hazard risks,and toxicity observed in preclinical/clinical studies of ADCs,summarized the preclinical studies of Adcetris(brentuximab vedotin)and Kadcyla(ado-trastuzumab emtansine),and suggested a better strategy of ADCs in preclinical safety evaluation.
